Is HBeAg loss a sign of recovery? How far is it from a functional cure?

Separate the three kinds of negative

Hepatitis B reports mix up three different "negatives": undetectable HBV DNA, HBeAg loss, and HBsAg loss. They mean very different things, and they carry very different weight for treatment and prognosis.

HBV DNA reflects how actively the virus is replicating. HBeAg is an antigen the virus produces and is often linked to active replication. HBsAg positivity means surface antigen is still present. One result changing does not replace the whole picture, and one report is a poor basis for deciding you are close to a cure.

HBeAg loss is not the same as anti-HBe seroconversion

HBeAg loss means the antigen was not detected this time. HBeAg seroconversion means HBeAg is gone and anti-HBe has appeared. The two often happen in sequence, but they are not the same event.

Testing method also matters: some laboratories report only positive or negative, while others report a quantitative value. Reagents, reference ranges, and lower limits differ between laboratories, so a single result that sits just below the reference range is best confirmed with the same method before you and your clinician interpret the trend.

Why HBeAg loss is encouraging but not a cure

For many people, HBeAg loss, especially seroconversion with anti-HBe, is a sign that the immune system is gaining more control over the virus. It often means hepatitis activity may decrease and is worth recording in follow-up.

It is not a functional cure. Functional cure usually means HBsAg stays undetectable after treatment stops, with HBV DNA below the limit of detection, and sometimes anti-HBs appears. HBeAg loss may be years away from that point, and some people remain HBeAg negative for years without ever clearing HBsAg.

HBeAg-negative can still be active hepatitis

Another common mistake is to treat HBeAg negativity as "nothing to worry about". Some people have HBeAg-negative chronic hepatitis B: precore or basal core promoter variants stop the virus from producing e antigen, but HBV DNA may still be substantial, ALT may fluctuate, and liver inflammation and fibrosis can still progress.

So HBeAg alone cannot tell you where you stand. HBV DNA, ALT/AST, quantitative HBsAg, platelets, ultrasound or fibrosis assessment need to be read together before a clinician can judge the phase and whether treatment is needed.

What to check at follow-up

Keep a trend table for every visit: date, HBeAg and anti-HBe, HBV DNA value and unit, quantitative HBsAg, ALT/AST, platelets, ultrasound or elastography. When results come from different hospitals or assays, check units and reference ranges first.

If you take entecavir, tenofovir, or another antiviral, read HBeAg changes together with treatment duration and HBV DNA. Do not stop or reduce medicine on your own because one result turned negative. Stopping needs a clinician's assessment of cirrhosis, HBsAg status, duration of viral suppression, and follow-up capacity.

Questions to ask at your next visit

1. Is this HBeAg loss, or is it already anti-HBe seroconversion?
2. Was the test qualitative or quantitative? Should it be repeated with the same method?
3. Where do my HBV DNA, ALT, and quantitative HBsAg stand now?
4. Am I closer to immune control or to HBeAg-negative chronic hepatitis?
5. Do I need fibrosis assessment or liver cancer surveillance?
6. If I am on treatment, is my response as expected? What would we need before discussing stopping?
7. Which tests are next, when, and which changes should make me contact the clinic earlier?

Action checklist

Keep your most recent HBeAg, anti-HBe, HBV DNA, quantitative HBsAg, and ALT results in one folder. Ask whether the test was qualitative or quantitative and whether it needs confirmation. Do not stop antivirals because of one HBeAg-negative result. Build a trend table before the visit. Seek care promptly for jaundice, dark urine, marked fatigue, or abdominal swelling.